Bryan Roberts

Bryan joined Venrock in 1997. He is based in Palo Alto and seeks to partner with early-stage entrepreneurs innovating across the healthcare and life sciences industries. Bryan is currently involved with several companies across therapeutics, genomics, and HCIT, including 10X Genomics, Devoted Health, Element Biosciences, Encoded Therapeutics, Grand Rounds, and Lyra Health. Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan).

Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He received his B.A. from Dartmouth College.